Example Trial: TGF- β resistant CTLs in HD and NHL Dose levels and target toxicity Target toxicity rate: 0.20 Dose Group Dose Increase of Dosage (Modified Fibonacci) Prior Probability of Toxicity 1 Day 0 2 x 10 7 cells/m 2 D (2) 0.05 Day 14 2 x 10 7 cells/m 2 2 Day 0 6 x 10 7 cells/m 2 3xD (3.3) 0.08 Day 14 6 x 10 7 cells/m 2 3 Day 0 1.5 x 10 8 cells/m 2 7.5xD (5.0) 0.25 Day 14 1.5 x 10 8 cells/m 2
Example CRM Simulations for Trial Average Number of Toxicity 1 1.5 2 2.5 3 Scenario 1 (0.05,0.08,0.25) Scenario 2 (0.05,0.08,0.21) Scenario 3 (0.05,0.15,0.30) Numbers 3+3 Exponential Logistic
Greene S, Benedetti J, Crowley J. Clinical Trials in Oncology, 2nd ed. Florida, Chapman and Hall CRC. 2003.
Chevret S. Statistical Methods for Dose-Finding Experiments, John-Wiley and Sons, 2006.
Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med. 14(11):1149-61, 1995.
Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics. 54:251-264, 1998.
Zhang W, Sargent DJ, Mandrekar S. An adaptive dose-finding design incorporating both toxicity and efficacy. Statistics in Medicine online. Oct. 2005.
Diggle PJ, Liang, KY, Zeger SL. Analysis of Longitudinal Data. New York, Oxford University Press, 1994.
Walker EB, Disis ML. Monitoring immune responses in cancer patients receiving tumor vaccines. Intern. Rev. Immunol. 22:283-319, 2003.
Salazar LG, Fikes J, Southwood S, Ishiokka G, Knutson KL, Gooley TA, Shciffman K, Disis ML. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin. Cancer Research. 9:5559-5565, 2003.
Caliguiri MA, Velardi A, Scheinberg DA, Borrello IM. Immunotherapeutic approaches for hematologic malignancies. Hematology. 337-353, 2004.
Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodegaus L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Sthephens J, Byrd JC, Grever MR, Caliguiri MA, Porcu P. Combination immunotherapy of B-cell non-Hodgkin’s lymphoma with rituximab and interleukin-2: A preclinical and phase I study. Clin. Cancer Research. 10:6101-611-, 2004.
Hoos A, Parmiano G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G for CVCTWG. A clinical development paradigm for cancer vaccines and related biologics. J Immunotherapy. 30(1): 1-15, 2007.
Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. JCO. 23(9): 2020-2027, 2005.